10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Neoline, an active ingredient of the processed aconite root in Goshajinkigan formulation, targets Nav1.7 to ameliorate mechanical hyperalgesia in diabetic mice.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Goshajinkigan (GJG), a traditional Japanese Kampo formula, has been shown to exhibit several pharmacological actions, including antinociceptive effects. Processed aconite root (PA), which is considered to be an active ingredient of GJG, has also been demonstrated to have an ameliorative effect on pain, such as diabetic peripheral neuropathic pain. We recently identified neoline as the active ingredient of both GJG and PA that is responsible for its effects against oxaliplatin-induced neuropathic pain in mice.

          Related collections

          Author and article information

          Journal
          J Ethnopharmacol
          Journal of ethnopharmacology
          Elsevier BV
          1872-7573
          0378-8741
          Sep 15 2020
          : 259
          Affiliations
          [1 ] Department of Pharmacotherapeutics, School of Pharmacy, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara, Tochigi, 324-8501, Japan; Advanced Education and Research Center for Kampo Medicine, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara, Tochigi, 324-8501, Japan. Electronic address: ynakatani@iuhw.ac.
          [2 ] Department of Pharmacotherapeutics, School of Pharmacy, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara, Tochigi, 324-8501, Japan. Electronic address: goronekanako@gmail.com.
          [3 ] Department of Pharmacotherapeutics, School of Pharmacy, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara, Tochigi, 324-8501, Japan. Electronic address: sw_clover_en@icloud.com.
          [4 ] Department of Pharmacotherapeutics, School of Pharmacy, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara, Tochigi, 324-8501, Japan. Electronic address: prism_ksgh@icloud.com.
          [5 ] Department of Neuropharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan. Electronic address: c162703@ed.phar.nagoya-cu.ac.jp.
          [6 ] Department of Neuropharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan. Electronic address: c182704@ed.phar.nagoya-cu.ac.jp.
          [7 ] Department of Pharmacotherapeutics, School of Pharmacy, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara, Tochigi, 324-8501, Japan. Electronic address: 1031145@g.iuhw.ac.jp.
          [8 ] Department of Pharmacotherapeutics, School of Pharmacy, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara, Tochigi, 324-8501, Japan. Electronic address: 1231179@g.iuhw.ac.jp.
          [9 ] Department of Neuropharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan. Electronic address: 1331023@g.iuhw.ac.jp.
          [10 ] Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan. Electronic address: vxv.be3al2si6o18.licht@gmail.com.
          [11 ] Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan. Electronic address: ishiuchi@phar.nagoya-cu.ac.jp.
          [12 ] Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan. Electronic address: makino@phar.nagoya-cu.ac.jp.
          [13 ] International University of Health and Welfare, Tokyo Office, Amity-Nogizaka-BIdg 1-24-1 Minamiaoyama, Minato-ku, Tokyo, 107-0062, Japan.
          [14 ] Department of Neuropharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan. Electronic address: ohsawa@phar.nagoya-cu.ac.jp.
          [15 ] Department of Pharmacotherapeutics, School of Pharmacy, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara, Tochigi, 324-8501, Japan; Advanced Education and Research Center for Kampo Medicine, International University of Health and Welfare, 2600-1 Kitakanemaru, Ohtawara, Tochigi, 324-8501, Japan. Electronic address: amano-pharmacothera@iuhw.ac.jp.
          Article
          S0378-8741(19)34578-7
          10.1016/j.jep.2020.112963
          32439405
          f73e63bd-fc0c-42cd-8357-98ae0bf104a0
          Copyright © 2020 Elsevier B.V. All rights reserved.
          History

          Voltage-gated sodium channel,Diabetic mice,Goshajinkigan,Nav1.7,Processed aconite root,Neoline

          Comments

          Comment on this article